This preprint presents a systematic performance and lifecycle assessment of five biologically derived material classes — mycelium composites, hemp biocomposites, bacterial cellulose, seaweed-derived biopolymers, and chitin bioplastics — evaluated against primary application classes currently dominated by synthetic polymers. For each material class, commercially demonstrated or peer-reviewed performance data are presented for mechanical properties, water resistance, thermal performance, biodegradation rate, and production system requirements. A cross-application performance matrix identifies where biological alternatives currently meet or exceed synthetic polymer performance, where gaps remain, and the specific research requirements to close those gaps. No application class is claimed to be fully substituted at current commercial readiness.
John Carter (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: